New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida Phase III RESONATE-2: Frontline Ibrutinib.

Slides:



Advertisements
Similar presentations
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.
Advertisements

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Second Interim Analysis of a Phase 3 Study of Idelalisib Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
IMAJEM, a Substudy of IFM 2009: Prognostic Role of MRI and PET/CT in MM New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida Brentuximab Vedotin + ESHAP in R/R Classical.
May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.
May 29 - June 2, 2015 Borealis-1: Apatorsen + Gemcitabine/Cisplatin for Pts With Advanced Bladder Cancer CCO Independent Conference Highlights of the 2015.
May 29 - June 2, 2015 Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer CCO Independent Conference.
Value of MRD to Predict PFS in MM: Results From IFM/DFCI 2009
Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida ARRAY : Phase II Trial of Carfilzomib.
POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida First-in-Human Trial: BCMA- Targeted CAR.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
May 29 - June 2, 2015 KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1- Positive Extensive-Stage SCLC CCO Independent Conference.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida Venetoclax Monotherapy in R/R CLL With del(17p)
CCO Independent Conference Coverage
CCO Independent Conference Coverage
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida TOURMALINE-MM1: Improved PFS With Ixazomib.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Rovalpituzumab Tesirine Safe, Active in Previously Treated SCLC *CCO.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida Venetoclax + Decitabine or Azacitidine in.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
GALLIUM: Obinutuzumab- vs Rituximab-Based Immunochemotherapy in Patients With Untreated Follicular Lymphoma New Findings in Hematology: Independent Conference.
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.
Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.
CCO Independent Conference Coverage
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.
PYRAMID: Frontline R-CHOP ± Bortezomib in Non-GCB DLBCL
: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.
CCO Independent Conference Highlights
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
CCO Independent Conference Coverage
CCO Independent Conference Coverage
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
CCO Independent Conference Coverage
Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
REMARC: Lenalidomide vs Placebo as Maintenance Therapy in Patients With DLBCL Following R-CHOP Induction New Findings in Hematology: Independent Conference.
RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML New Findings in Hematology: Independent.
ASSIST-FL: Rituximab Biosimilar GP2013 vs Rituximab in Treatment-Naive Patients With Advanced Follicular Lymphoma New Findings in Hematology: Independent.
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma New Findings in Hematology: Independent Conference Coverage.
New Findings in Hematology: Independent Conference Coverage
New Findings in Hematology: Independent Conference Coverage
KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
Phase III PROUD-PV: Ropeginterferon α-2b Noninferior to Hydroxyurea in Polycythemia Vera New Findings in Hematology: Independent Conference Coverage of.
New Findings in Hematology: Independent Conference Coverage
Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
CCO Independent Conference Coverage
Phase Ib MMY1001: Daratumumab Plus Pom/Dex for Patients With R/R MM
Rigosertib + Azacitidine in Patients With Higher-Risk MDS
Goede V et al. Proc ASH 2014;Abstract 3327.
New Findings in Hematology: Independent Conference Coverage
Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis New Findings in Hematology: Independent Conference Coverage.
Combination Ruxolitinib + Sonidegib in Myelofibrosis
New Findings in Hematology: Independent Conference Coverage
WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL
What is the best frontline regimen for CLL patients
Presentation transcript:

New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida Phase III RESONATE-2: Frontline Ibrutinib vs Chlorambucil in Elderly Patients With CLL *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. This program is supported by educational grants from Amgen, Celgene Corporation, Incyte, Merck, Seattle Genetics, and Takeda Oncology.

RESONATE-2: Background  CLL primarily seen in older pts who often have comorbidities [1] –Chlorambucil standard frontline therapy for older pts; fludarabine may be too toxic for older or frail pts  Ibrutinib: first-in-class oral BTK inhibitor –FDA- and EMA-approved for pts with previously treated CML, including those with del(17p) and by EMA for those with mutated TP53  Phase III RESONATE trial of ibrutinib in relapsed/refractory CLL showed 78% reduction in risk of progression and 57% reduction in risk of death vs ofatumumab [2]  Phase II PCYC-1102 trial in treatment-naive pts with CLL showed 84% ORR and 96% 30-mo PFS and 97% 30-mo OS with 81% of pts continuing ibrutinib at 3 yrs [3]  Current RESONATE-2 trial evaluated ibrutinib in older pts with treatment-naive CLL or SLL 1. Thurmes P, et al. Leuk Lymphoma. 2008;49: Byrd JC, et al. N Engl J Med. 2014;37: Byrd JC, et al. Blood. 2015;124: Slide credit: clinicaloptions.comclinicaloptions.com

Phase III RESONATE-2: Study Design  Open-label, randomized trial  Primary endpoint: IRC-evaluated PFS  Secondary endpoints: OS, ORR, hematologic improvement, safety Treatment-naive CLL pts 65 yrs of age or older; for pts yrs, comorbidity that precludes FCR; no warfarin use; no del(17p) (N = 269) Ibrutinib 420 mg QD until PD or unacceptable toxicity (n = 136) Chlorambucil 0.5 mg/kg* Days 1 and 15 of 28-d cycle up to 12 cycles (n = 133) PCYC-1116 extension study after IRC- confirmed progression Stratified by ECOG PS 0-1 vs 2 Rai stage III-IV vs ≤ II Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com Crossover upon PD (n = 43) *Up to 0.8 mg/kg maximum.

RESONATE-2: Baseline Characteristics Characteristic Ibrutinib (n = 136) Chlorambucil (n = 133) Median age, yrs (range)  70 yrs or older, % 73 (65-89) (65-90) 70 ECOG PS 2, %89 Rai stage III or IV, %4447 CIRS score > 6, %3133 Creatinine clearance < 60 mL/min, %4450 Bulky disease ≥ 5 cm, %4030 β 2 -microglobulin > 3.5 mg/L, %6367 Hemoglobin ≤ 11 g/dL, %3841 Platelet count ≤ 100,000/mm³, %2621 del(11q), %2119 Unmutated IGVH, %4345 Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com

RESONATE-2: PFS (Primary Endpoint)  At median follow-up of 18.4 mos, 84% vs 91% reduction in risk of disease progression or death with ibrutinib by independent vs investigator assessment  PFS results not dependent on age, Rai stage, ECOG PS, or bulky disease  1 Richter’s transformation in chlorambucil arm; none on ibrutinib arm Outcome Ibrutinib (n = 136) Chlorambucil (n = 133) HR (95% CI) P Value Independent Assessment Median PFS, mosNE ( ) < mo PFS rate, %9052 Investigator Assessment Median PFS, mosNE ( ) < mo PFS rate, %9445 Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com

RESONATE-2: PFS in High-Risk Subgroups by Investigator Assessment  In ibrutinib arm, 92% 18-mo PFS rate in IGHV-mutated subgroup vs 95% in unmutated subgroup Median PFS, Mos Ibrutinib (n = 136) Chlorambucil (n = 133) HR P Value del(11q) subgroupNR90.02 <.0001 Unmutated IGHV subgroup NR90.06 <.0001 Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com

RESONATE-2: OS  84% reduction in risk of death with ibrutinib Outcome Ibrutinib (n = 136) Chlorambucil (n = 133) HR (95% CI) P Value Median OS, mosNE 0.16 ( ) mo OS rate, %9884 Deaths, n317 Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com

RESONATE-2: Best Response by Investigator Assessment  90% of pts responded to ibrutinib vs 35% to chlorambucil (P <.0001)  ORR at 8 mos: 82% with ibrutinib vs 30% with chlorambucil Response, % Ibrutinib (n = 136) Chlorambucil (n = 133) CR/CRi105 nPR12 PR7629 PR-L30 SD640 PD120 Sustained improvement in Hb in pts with anemia* 8445 Sustained improvement in platelets in pts with thrombocytopenia † 7743 Tedeschi A, et al. ASH Abstract 495. *P <.0001; † P =.0054 Slide credit: clinicaloptions.comclinicaloptions.com

RESONATE-2: Exposure to Study Treatment Parameter Ibrutinib (n = 136) Chlorambucil (n = 133) Median duration of study treatment, mos (range) 17.4 ( )7.1 ( ) Dose reduction, n (%)13 (10)25 (19) Continuing treatment at end of study, n (%)118 (87)0 Completing maximum of 12 cycles of chlorambucil, n (%) NA53 (40) Mean chlorambucil dose, mg/kg (range)NA0.6 ( ) Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com

RESONATE-2: Discontinuation of Ibrutinib  13 of 14 who discontinued ibrutinib due to AEs or progression remained alive at median follow-up of 10 mos after discontinuation Outcome, n Ibrutinib (n = 136) Discontinued ibrutinib due to AEs12  Died1  Progression of disease after discontinuation3  Subsequent therapy without progression3  Progression free without additional therapy5 Discontinued therapy due to progression on therapy 2 Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com

RESONATE-2: Adverse Events Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com  Pts with grade 3 HTN (n = 6) managed with anti-HTN drugs, did not require dose reduction of ibrutinib; 4 had history of HTN  Among pts with atrial fibrillation (n = 8), 2 discontinued ibrutinib –7 of 8 with history of HTN, CAD, and/or myocardial ischemia  Among pts with major bleeding (n = 6), 3 discontinued ibrutinib –3 of 6 on concomitant aspirin, vitamin E, or low-molecular-weight heparin Parameter Ibrutinib (n = 136) Chlorambucil (n = 133) Median duration of study treatment, mos (range) 17.4 ( )7.1 ( ) Selected AEs, %  Hypertension140  Atrial fibrillation61  Major hemorrhage42

RESONATE-2: Adverse Events  Majority of AEs on ibrutinib arm were grade 1; did not result in treatment discontinuation  Fatigue, nausea, vomiting, cytopenias occurred more frequently with chlorambucil  Grade 3 maculopapular rash in 3% of pts on ibrutinib and 2% of those on chlorambucil Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com

RESONATE-2: Conclusions  Phase III trial of ibrutinib vs chlorambucil in elderly treatment-naive pts with CLL –84% reduction in risk of progression by independent assessment and 84% reduction in risk of death with ibrutinib –Improved bone marrow function (↑ Hb, platelets) with ibrutinib –Most pts (87%) continued ibrutinib with a median follow-up of 1.5 yrs  Ibrutinib shows favorable benefit/risk profile vs traditional chemotherapy in elderly pts with CLL/SLL Tedeschi A, et al. ASH Abstract 495. Slide credit: clinicaloptions.comclinicaloptions.com

Go Online for More CCO Coverage of ASH 2015! Short slideset summaries of all the key data Additional CME-certified analyses with expert faculty commentary on all the key studies in:  Acute leukemias/chronic leukemias  Myeloma/plasma cell disorders  Lymphomas  MDS and myeloproliferative neoplasms clinicaloptions.com/oncology